^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    19h
    AB1MALT: Bronchoscopic Microwave Ablation of Lung Tissue (clinicaltrials.gov)
    P=N/A, N=35, Active, not recruiting, Creo Medical Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    19h
    C-Raven, a Virtual Tobacco Cessation Intervention in the Community (clinicaltrials.gov)
    P4, N=10, Completed, Johns Hopkins University | Active, not recruiting --> Completed | N=30 --> 10
    Trial completion • Enrollment change
    19h
    A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P1, N=42, Terminated, Prelude Therapeutics | Trial completion date: Apr 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date • First-in-human
    20h
    FROSTBITE-3: EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing (clinicaltrials.gov)
    P4, N=250, Recruiting, Vanderbilt-Ingram Cancer Center | Phase classification: P3 --> P4
    Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    20h
    EMPOWER 3: Improving Palliative Care Health Literacy and Utilization (clinicaltrials.gov)
    P=N/A, N=172, Active, not recruiting, Tulane University | Recruiting --> Active, not recruiting | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    LDH elevation
    21h
    COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (clinicaltrials.gov)
    P1/2, N=933, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Lonsurf (trifluridine/tipiracil)
    21h
    Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial
    |
    AiRuiLi (adebrelimab)
    22h
    APART-LUNG: Physical Activity During Radiation Therapy for Lung Cancer (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, University Hospital Schleswig-Holstein
    New trial
    22h
    3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial (clinicaltrials.gov)
    P1/2, N=89, Not yet recruiting, St. Joseph's Healthcare Hamilton | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Nov 2027 --> Nov 2028
    Trial completion date • Trial primary completion date
    23h
    A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=37, Completed, Memorial Sloan Kettering Cancer Center | N=90 --> 37 | Trial completion date: Jun 2026 --> Jan 2026 | Trial primary completion date: Jun 2026 --> Jan 2026 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Minimal residual disease
    23h
    A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (clinicaltrials.gov)
    P1, N=328, Recruiting, HC Biopharma Inc.
    New P1 trial
    |
    EGFR mutation
    |
    cisplatin • carboplatin • paclitaxel • docetaxel • pemetrexed • etoposide IV
    24h
    KEYNOTE-G02: A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation (clinicaltrials.gov)
    P2, N=6, Terminated, Prelude Therapeutics | Trial completion date: Dec 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2027 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    Keytruda (pembrolizumab) • PRT3789